Jane Street’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Jane Street’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-88,000	Closed	-$8.97M	–	9657
2023 Q2	$8.97M	Sell	88,000 -9,400	-10%	-$890K	﹤0.01%	2027
2023 Q1	$8.86M	Buy	97,400 +66,300	+213%	+$3.89M	﹤0.01%	1767
2022 Q4	$1.18M	Sell	31,100 -332,600	-91%	-$11.4M	﹤0.01%	4718
2022 Q3	$9.14M	Buy	363,700 +345,200	+1,866%	+$9.57M	﹤0.01%	1794
2022 Q2	$562K	Sell	18,500 -44,300	-71%	-$1.32M	﹤0.01%	6511
2022 Q1	$2.06M	Buy	62,800 +23,600	+60%	+$700K	﹤0.01%	4699
2021 Q4	$1.03M	Sell	39,200 -21,200	-35%	-$1.64M	﹤0.01%	5834
2021 Q3	$6.08M	Buy	60,400 +18,900	+46%	+$2.22M	﹤0.01%	2453
2021 Q2	$5.87M	Buy	41,500 +6,500	+19%	+$734K	﹤0.01%	2391
2021 Q1	$3.49M	Buy	35,000 +4,400	+14%	+$513K	﹤0.01%	2966
2020 Q4	$3.78M	Sell	30,600 -4,900	-14%	-$644K	﹤0.01%	2495
2020 Q3	$3.46M	Buy	35,500 +9,600	+37%	+$1.2M	﹤0.01%	2265
2020 Q2	$4.04M	Buy	25,900 +16,800	+185%	+$2.55M	﹤0.01%	2112
2020 Q1	$1.31M	Buy	+9,100	New	+$1.76M	﹤0.01%	2485

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jane Street's RETA Position: Q3 2023 in Review

Jane Street sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 70,516 shares — an estimated $7.19M sold.

Jane Street first reported a position in RETA in Q1 2019 and held it in 15 quarters. The position peaked at $8.04M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Jane Street reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Jane Street sold 70,516 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $7.19M.
Jane Street first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 15 quarters.
Jane Street's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $8.04M in Q2 2020.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Jane Street's 13F filing for Q3 2023, filed 15 Nov 2023.